Using Boolean Logic Modeling of Gene Regulatory Networks to Exploit the Links Between Cancer and Metabolism for Therapeutic Purposes

GPU Accelerated Drug Application on Signaling Pathways Containing Multiple Faults Using Boolean Networks

Cell growth is governed by the flow of information from growth factors to transcription factors. This flow involves protein-protein interactions known as a signaling pathway, which triggers the cell division. The biological network in the presence of malfunctions leads to a rapid cell division without any necessary input conditions. The effect of these malfunctions or faults can be observed if it is simulated explicitly in the Boolean derivative of the biological networks. The consequences thus produced can be nullified to a large extent, with the application of a reduced combination of drugs. This paper provides an insight into the behavior of the signaling pathway in the presence of multiple concurrent malfunctions. First, we simulate the behavior of malfunctions in the Boolean networks. Next, we apply the drug therapy to reduce the effects of malfunctions. In our approach, we introduce a parameter called probabilistic_score, which identifies the reduced drug combinations without prior knowledge of the malfunctions, and it is more beneficial in realistic cancerous conditions. The combinations of different custom drug inhibition points are chosen to produce more efficient results than known drugs. Our approach is significantly faster as GPU acceleration has been carried out during modeling the multiple faults/malfunctions in the Boolean networks.

Computational prediction of intracellular targets of wild-type or mutant vesicular stomatitis matrix protein

The matrix (M) protein of vesicular stomatitis virus (VSV) has a complex role in infection and immune evasion, particularly with respect to suppression of Type I interferon (IFN). Viral strains bearing the wild-type (wt) M protein are able to suppress Type I IFN responses. We recently reported that the 22–25 strain of VSV encodes a wt M protein, however its sister plaque isolate, strain 22–20, carries a M[MD52G] mutation that perturbs the ability of the M protein to block NFκB, but not M-mediated inhibition of host transcription. Therefore, although NFκB is activated in 22–20 infected murine L929 cells infected, no IFN mRNA or protein is produced. To investigate the impact of the M[D52G] mutation on immune evasion by VSV, we used transcriptomic data from L929 cells infected with wt, 22–25, or 22–20 to define parameters in a family of executable logical models with the aim of discovering direct targets of viruses encoding a wt or mutant M protein. After several generations of pruning or fixing hypothetical regulatory interactions, we identified specific predicted targets of each strain. We predict that wt and 22–25 VSV both have direct inhibitory actions on key elements of the NFκB signaling pathway, while 22–20 fails to inhibit this pathway.

Cryptotanshinone Induces Cell Death in Lung Cancer by Targeting Aberrant Feedback Loops

Signaling pathways oversee highly efficient cellular mechanisms such as growth, division, and death. These processes are controlled by robust negative feedback loops that inhibit receptor-mediated growth factor pathways. Specifically, the ERK, the AKT, and the S6K feedback loops attenuate signaling via growth factor receptors and other kinase receptors to regulate cell growth. Irregularity in any of these supervised processes can lead to uncontrolled cell proliferation and possibly Cancer. These irregularities primarily occur as mutated genes, and an exhaustive search of the perfect drug combination by performing experiments can be both costly and complex. Hence, in this paper, we model the Lung Cancer pathway as a Modified Boolean Network that incorporates feedback. By simulating this network, we theoretically predict the drug combinations that achieve the desired goal for the majority of mutations. Our theoretical analysis identifies Cryptotanshinone, a traditional Chinese herb derivative, as a potent drug component in the fight against cancer. We validated these theoretical results using multiple wet lab experiments carried out on H2073 and SW900 lung cancer cell lines.

Integration of Genome Scale Metabolic Networks and Gene Regulation of Metabolic Enzymes With Physiologically Based Pharmacokinetics

The scope of physiologically based pharmacokinetic (PBPK) modeling can be expanded by assimilation of the mechanistic models of intracellular processes from systems biology field. The genome scale metabolic networks (GSMNs) represent a whole set of metabolic enzymes expressed in human tissues. Dynamic models of the gene regulation of key drug metabolism enzymes are available. Here, we introduce GSMNs and review ongoing work on integration of PBPK, GSMNs, and metabolic gene regulation. We demonstrate example models.